Intercell and Biological E. Ltd. announce successful completion of investigational
Japanese Encephalitis vaccine pivotal Phase II/III study in India
Positive results from first pivotal immunogenicity Phase II/III trial in endemic region to prevent Japanese Encephalitis (JE) in children
19-Sep-2011 -
Intercell AG and its partner Biological E. Ltd. announced the successful completion of a pediatric Phase II/III study for the vaccine to protect children from Japanese Encephalitis (JE). Analysis of the pivotal Phase III safety and immunogenicity data showed positive results and that the study ...
Japanese encephalitis
phase III studies